checkAd

DGAP-News Minapharm Pharmaceuticals: RDIF and Minapharm Agree to Produce Over 40 Million Doses of the Sputnik V Vaccine in Egypt

Nachrichtenquelle: EQS Group AG
22.04.2021, 10:00  |  125   |   |   

DGAP-News: Minapharm Pharmaceuticals / Key word(s): Agreement/Miscellaneous
Minapharm Pharmaceuticals: RDIF and Minapharm Agree to Produce Over 40 Million Doses of the Sputnik V Vaccine in Egypt

22.04.2021 / 10:00
The issuer is solely responsible for the content of this announcement.


RDIF and Minapharm Agree to Produce Over 40 Million Doses of the Sputnik V Vaccine in Egypt

Moscow/Cairo/Berlin, April 22, 2021 - The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund), Egypt's Minapharm, the regional leader in recombinant DNA technology, and its Berlin-based subsidiary ProBioGen AG announce the agreement to produce over 40 million doses per year of the world's first registered vaccine against COVID-19, Sputnik V.

The parties intend to commence technology transfer immediately. The rollout of the vaccine is expected in 3Q 2021.

RDIF and Minapharm will initially supply over 40 million doses per year. Production will take place in Minapharm's biotech facility in Cairo for global distribution.

Minapharm's German subsidiary, ProBioGen AG, aims to undertake efforts for process optimization to further increase the production scale taking advantage of its expertise in viral vector technology and manufacturing process development for vaccines and gene therapy.

To date, Sputnik V has been registered in 61 countries globally covering a total population of over 3 billion people. Sputnik V vaccine demonstrated efficacy of 97.6%, based on the analysis of data on the infection rate of coronavirus among those in Russia vaccinated with both components of the vaccine.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund, commented:

"Agreement with Minapharm marks our first partnership in MENA region to produce Sputnik V. RDIF is in cooperation with the leading pharmaceutical producers globally as Sputnik V is registered in 61 countries. The Russian vaccine is highly efficient and trusted by regulators around the world and makes a huge contribution in the fight against coronavirus."

Seite 1 von 3




0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

DGAP-News Minapharm Pharmaceuticals: RDIF and Minapharm Agree to Produce Over 40 Million Doses of the Sputnik V Vaccine in Egypt DGAP-News: Minapharm Pharmaceuticals / Key word(s): Agreement/Miscellaneous Minapharm Pharmaceuticals: RDIF and Minapharm Agree to Produce Over 40 Million Doses of the Sputnik V Vaccine in Egypt 22.04.2021 / 10:00 The issuer is solely responsible …

Nachrichten des Autors

Titel
Titel
Titel
Titel